Analysts think VTGN stock price could increase by 243%
Oct 09, 2025, 11:25 AM
-0.12%
What does VTGN do
VistaGen Therapeutics, a biopharmaceutical company based in South San Francisco, develops treatments for anxiety and depression using intranasal pherines and other therapies targeting central nervous system disorders. The company’s pipeline includes five clinical-stage investigational agents and went public on October 18, 2010.
6 analysts think VTGN stock price will increase by 242.96%. The current median analyst target is $13.77 compared to a current stock price of $4.01. The lowest analysts target is $12.12 and the highest analyst target is $19.95.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.